A citation-based method for searching scientific literature

Lutz Wollin, Isabelle Maillet, Valérie Quesniaux, Alexander Holweg, Bernhard Ryffel. J Pharmacol Exp Ther 2014
Times Cited: 308







List of co-cited articles
627 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
52

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
348
39

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Frank Hilberg, Gerald J Roth, Martin Krssak, Susanna Kautschitsch, Wolfgang Sommergruber, Ulrike Tontsch-Grunt, Pilar Garin-Chesa, Gerd Bader, Andreas Zoephel, Jens Quant,[...]. Cancer Res 2008
682
32

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
29

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
641
27

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
21

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
20

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Katrin E Hostettler, Jun Zhong, Eleni Papakonstantinou, George Karakiulakis, Michael Tamm, Petra Seidel, Qingzhu Sun, Jyotshna Mandal, Didier Lardinois, Christopher Lambers,[...]. Respir Res 2014
134
19

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
430
18

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
985
16

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
404
16

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Lutz Wollin, Jörg H W Distler, Elizabeth F Redente, David W H Riches, Susanne Stowasser, Rozsa Schlenker-Herceg, Toby M Maher, Martin Kolb. Eur Respir J 2019
70
22

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
14

Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Jingang Huang, Christian Beyer, Katrin Palumbo-Zerr, Yun Zhang, Andreas Ramming, Alfiya Distler, Kolja Gelse, Oliver Distler, Georg Schett, Lutz Wollin,[...]. Ann Rheum Dis 2016
106
12

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
882
12

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Luca Richeldi, Vincent Cottin, Roland M du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker-Herceg, Susanne Stowasser, Kevin K Brown. Respir Med 2016
210
12

Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Jingang Huang, Christiane Maier, Yun Zhang, Alina Soare, Clara Dees, Christian Beyer, Ulrike Harre, Chih-Wei Chen, Oliver Distler, Georg Schett,[...]. Ann Rheum Dis 2017
79
13

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Bruno Crestani, John T Huggins, Mitchell Kaye, Ulrich Costabel, Ian Glaspole, Takashi Ogura, Jin Woo Song, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Lancet Respir Med 2019
78
14

Idiopathic Pulmonary Fibrosis.
David J Lederer, Fernando J Martinez. N Engl J Med 2018
451
11

An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis.
R Gisli Jenkins, Bethany B Moore, Rachel C Chambers, Oliver Eickelberg, Melanie Königshoff, Martin Kolb, Geoffrey J Laurent, Carmel B Nanthakumar, Mitchell A Olman, Annie Pardo,[...]. Am J Respir Cell Mol Biol 2017
127
10

Idiopathic pulmonary fibrosis.
Talmadge E King, Annie Pardo, Moisés Selman. Lancet 2011
10

Effects of nintedanib on the microvascular architecture in a lung fibrosis model.
Maximilian Ackermann, Yong Ook Kim, Willi L Wagner, Detlef Schuppan, Cristian D Valenzuela, Steven J Mentzer, Sebastian Kreuz, Detlef Stiller, Lutz Wollin, Moritz A Konerding. Angiogenesis 2017
75
13

Novel Mechanisms for the Antifibrotic Action of Nintedanib.
Sunad Rangarajan, Ashish Kurundkar, Deepali Kurundkar, Karen Bernard, Yan Y Sanders, Qiang Ding, Veena B Antony, Jianhua Zhang, Jaroslaw Zmijewski, Victor J Thannickal. Am J Respir Cell Mol Biol 2016
94
9

Nintedanib: from discovery to the clinic.
Gerald J Roth, Rudolf Binder, Florian Colbatzky, Claudia Dallinger, Rozsa Schlenker-Herceg, Frank Hilberg, Stefan-Lutz Wollin, Rolf Kaiser. J Med Chem 2015
142
9

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
876
9

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Am J Respir Crit Care Med 2018
103
9

Pirfenidone in idiopathic pulmonary fibrosis.
H Taniguchi, M Ebina, Y Kondoh, T Ogura, A Azuma, M Suga, Y Taguchi, H Takahashi, K Nakata, A Sato,[...]. Eur Respir J 2010
608
9

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
Ulrich Costabel, Yoshikazu Inoue, Luca Richeldi, Harold R Collard, Inga Tschoepe, Susanne Stowasser, Arata Azuma. Am J Respir Crit Care Med 2016
151
8

The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.
Friedrich Grimminger, Andreas Günther, Carlo Vancheri. Eur Respir J 2015
82
9

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.
Enrico Conte, Elisa Gili, Evelina Fagone, Mary Fruciano, Maria Iemmolo, Carlo Vancheri. Eur J Pharm Sci 2014
166
8

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
Hisashi Oku, Toshikatsu Shimizu, Tomoji Kawabata, Morio Nagira, Ichiro Hikita, Azumi Ueyama, Shuuichi Matsushima, Mikinori Torii, Akinori Arimura. Eur J Pharmacol 2008
265
8


Idiopathic pulmonary fibrosis.
Luca Richeldi, Harold R Collard, Mark G Jones. Lancet 2017
499
8

Idiopathic pulmonary fibrosis: pathogenesis and management.
Giacomo Sgalla, Bruno Iovene, Mariarosaria Calvello, Margherita Ori, Francesco Varone, Luca Richeldi. Respir Res 2018
139
7

Idiopathic pulmonary fibrosis.
Fernando J Martinez, Harold R Collard, Annie Pardo, Ganesh Raghu, Luca Richeldi, Moises Selman, Jeffrey J Swigris, Hiroyuki Taniguchi, Athol U Wells. Nat Rev Dis Primers 2017
326
7

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
539
7

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Ian Glaspole, Marilyn K Glassberg, David R Kardatzke, Monica Daigl, Klaus-Uwe Kirchgaessler, Lisa H Lancaster,[...]. Lancet Respir Med 2017
144
7

Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.
N I Chaudhary, G J Roth, F Hilberg, J Müller-Quernheim, A Prasse, G Zissel, A Schnapp, J E Park. Eur Respir J 2007
252
7

Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease.
Elizabeth F Redente, Martin A Aguilar, Bart P Black, Benjamin L Edelman, Ali N Bahadur, Stephen M Humphries, David A Lynch, Lutz Wollin, David W H Riches. Am J Physiol Lung Cell Mol Physiol 2018
36
19

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
Takashi Ogura, Hiroyuki Taniguchi, Arata Azuma, Yoshikazu Inoue, Yasuhiro Kondoh, Yoshinori Hasegawa, Masashi Bando, Shinji Abe, Yoshiro Mochizuki, Kingo Chida,[...]. Eur Respir J 2015
114
7

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Martin Kolb, Ganesh Raghu, Athol U Wells, Jürgen Behr, Luca Richeldi, Birgit Schinzel, Manuel Quaresma, Susanne Stowasser, Fernando J Martinez. N Engl J Med 2018
104
7

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Arata Azuma, Toshihiro Nukiwa, Eiyasu Tsuboi, Moritaka Suga, Shosaku Abe, Koichiro Nakata, Yoshio Taguchi, Sonoko Nagai, Harumi Itoh, Motoharu Ohi,[...]. Am J Respir Crit Care Med 2005
621
7

Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
Fernando J Martinez, Joao A de Andrade, Kevin J Anstrom, Talmadge E King, Ganesh Raghu. N Engl J Med 2014
294
6


The impact of TGF-β on lung fibrosis: from targeting to biomarkers.
Isis E Fernandez, Oliver Eickelberg. Proc Am Thorac Soc 2012
352
6

Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Feng Liu, Li Wang, Hualin Qi, Jun Wang, Yi Wang, Wei Jiang, Liuqing Xu, Na Liu, Shougang Zhuang. Clin Sci (Lond) 2017
30
20

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Brett Ley, Jeffrey Swigris, Bann-Mo Day, John L Stauffer, Karina Raimundo, Willis Chou, Harold R Collard. Am J Respir Crit Care Med 2017
85
7

Lung transplantation for idiopathic pulmonary fibrosis.
Peter M George, Caroline M Patterson, Anna K Reed, Muhunthan Thillai. Lancet Respir Med 2019
61
9

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
Talmadge E King, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Phil Hormel, Lisa Lancaster, Paul W Noble, Steven A Sahn, Javier Szwarcberg, Michiel Thomeer,[...]. Lancet 2009
342
6

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Toby M Maher, Tamera J Corte, Aryeh Fischer, Michael Kreuter, David J Lederer, Maria Molina-Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, Katerina Samara, Frank Gilberg,[...]. Lancet Respir Med 2020
161
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.